Abstract:Background Neovascular glaucoma (NVG) often occurs secondary to ocular ischemic diseases and is refractory glaucoma. Intravitreal injection of bevacizumab offers a new approach to the rapid regression of anterior segment neovascularization and therefore is used as an adjunct therapy of NVG. However, the efficacy of intravitreal injection of bevacizumab combined with anti-glaucoma surgery NVG is still explorating. Objective This clinical study was to assess the efficacy and safety of intraocular injection of bevacizumab combined with trabeculectomy (Trab) or cyclophotocoagulation (CPC) for NVG and explore a optimal treating flowchart. Methods This study was approved by Ethic Committee of Peking University Third Hospital, and written informed consent was obtained prior to any medical procedure. This was a nonrandomized case control study. Twenty-three eyes of 23 patients with NVG were collected from January 2012 to March 2013 in Peking University Third Hospital. The patients were grouped to the Trab group (9 eyes) and the CPC group (14 eyes) with the matched demography between the two groups. Bevacizumab at the dose of 1.25 mg (50 μl) was initially injected via the anterior chamber to vitreous, and then the corresponding surgery was performed on the NVG eyes in different groups. The visual acuity, intraocular pressure (IOP) and treatment-related indexes were examined 1 week and 3 months after operation. The intraoperative and postoperative complications were evaluated. A flowchart of combination procedure for NVG was established. Results No significant difference was found in the demography between the two groups (all at P>0.05). The IOPs were (43.4±6.2), (15.6±3.0) and (19.7±3.2) mmHg before operation and 1 week, 3 months after operation in the Trab group, and those in the CPC group were (42.8±4.9), (25.4±7.5) and (23.3±6.6) mmHg, with significant differences between different groups and time points (Fgroup=28.817, P<0.001; Ftime=158.418, P<0.001; Finteraction=7.260, P=0.002), and it showed significant lowing of IOP in 1 week and 3 months after operation in comparison with before operation (both at P<0.001). The IOP was significantly higher in the CPC group than that in the Trab group at 1 week after operation (P<0.01), but no significant difference in IOP at 3 months between the two groups (P=0.095). At the third month after surgery, visual acuity declined in 3 eyes in the Trab group and 9 eyes in the CPC group, with a significant difference between them (P=0.042). The interval time from intraocular injection of bevacizumab to surgery and from surgery to sequential treatment was longer in the CPC group than that in the Trab group (P=0.002, 0.003). There was no complication in both groups. Conclusions Intravitreal injection of bevacizumab can not reduce IOP in the NGV with angle closure but lessen complication associated with anti-glaucoma surgery. The combination of bevacizumab and Trab provides more rapid control of IOP than the combination of bevacizumab and CPC, which is important for maintaining visual function in late stage of NVG eye. Key words: Angiogenesis inhibitor/therapeutic use; Antibodies, monoclonal, humanized/therapeutic use; Combined modality therapy; Glaucoma, neovascular/therapy; Intraocular pressure; Intravitreal injection; Trabeculectomy; Cyclophotocoagulation; Vascular endothelial growth factor/antagonist & inhibitor

Evaluation of surgical effectiveness for neovascular glaucoma

Comparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysis

Initial observation on treatment strategies for neovascular glaucoma

Comparison of Clinical Efficacy Between Intravitreal Bevacizumab Combined with Trabeculectomy and Intravitreal Bevacizumab Combined with Cyclophotocoagulation for Late Stage Neovascular Glaucoma

23G Minimally Invasive Vitrectomy Combined with Glaucoma Drainage Valve Implantation and Phacoemulsification Cataract Extraction for Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy with Vitreous Hemorrhage

Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis

Comparison of Three Methods for Glaucoma with a Cataract

Combined Trabeculectomy and Vitrectomy for Intractable Glaucoma with Severe Ocular Contusion Involving the Posterior Segment.

Innovative sequential treatment of neovascular glaucoma

Clinical oberservation of ciliary body cryotherapy,trabeculectomy and 5-FU in treatment of neovascular glaucoma

Efficacy of Combining Treatment Based on Clinical Stage in Neovascular Glaucoma

Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma - a retrospective interventional case series

The primary efficacy of trabeculectomy with immersion of mitomycin C and amniotic membrane implantation for refractory glaucoma

Comparison of the safety and efficacy of triple sequential therapy and transscleral cyclophotocoagulation for neovascular glaucoma in the angle-closure stage

Evaluation of the effectiveness of laser therapy for primary angle closure glaucoma with different extent of goniosynechia

Vitrectomy with Intraocular Cyclophotocoagulation for the Treatment of Neovascular Glaucoma

Clinical investigation on management of 19 cases malignant glaucoma after glaucoma surgery

Two-year outcomes of patients presenting to Sydney Eye Hospital with neovascular glaucoma

Clinical Research of Intravitreal Injection of Conbercept Combined with Different Methods in the Treatment of Neovascular Glaucoma

The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion

Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysis